Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;13(11):1676-1683.
doi: 10.1111/1759-7714.14442. Epub 2022 May 3.

Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited country

Soon Hin How  1 , Lye Mun Tho  2 , Chong Kin Liam  3 , Harissa H Hasbullah  4   5 , Gwo Fuang Ho  3 , Ibtisam Muhammad Nor  5 , Mau Ern Poh  3 , Kean Fatt Ho  6 , Muthukkumaran Thiagarajan  5 , Azlina Samsudin  7 , Azza Omar  8 , Choo Khoon Ong  9 , Yong Kek Pang  3 , Sing Yang Soon  10
Affiliations

Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited country

Soon Hin How et al. Thorac Cancer. 2022 Jun.

Abstract

Introduction: Immune checkpoint inhibitor (ICI) therapy is an established treatment for advanced non-small-cell lung cancer (NSCLC) and programmed death ligand-1 (PD-L1) expression is a recognized biomarker to determine response to therapy. We retrospectively analyzed NSCLC patients in the Malaysia Lung Cancer Registry (MLCR) and report on the clinical characteristics associated with PD-L1 expression and ICI use in Malaysia, a low- to middle-income country.

Methods: All 901 NSCLC patients in the MLCR who were diagnosed from January 1, 2017 to December 31, 2020 from 14 hospitals across the country were analyzed.

Results: Out of 901 patients, 505 had PDL-1 testing done with complete data available only in 489 patients. The most common histology was adenocarcinoma (84.7%) followed by squamous cell carcinoma (10.2%). The majority (95%) presented with stage 3 or 4. The number and percentage of patients with PDL-1 tumor proportion scores of ≥50%, 1-49%, and <1% were 138 (28.2%), 158 (32.3%), and 193 (39.5%), respectively. In multivariate analysis, the presence of genomic mutation is the only independent characteristic associated with negative PD-L1 expression (crude odds ratio 0.579, 95% confidence interval 0.399-0.840, p = 0.004). Of 292 patients eligible for ICI therapy, only 100 patients (34.2%) received ICIs. Seventy-eight patients received ICI therapy as first-line treatment, 15 patients as second-line treatment, and 7 patients as third-line treatment.

Conclusions: This is the first analysis on PD-L1 expression and ICI use in Malaysia. Despite the proven efficacy of ICI therapy, only 56% of our patients had PD-L1 tests performed and only 34.2% of eligible patients received ICIs.

Keywords: PDL-1; immunotherapy; lung cancer.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflict of interest pertaining to this manuscript

Figures

FIGURE 1
FIGURE 1
Programmed death ligand‐1 (PDL‐1) testing in non‐small‐cell lung cancer (NSCLC) patients
FIGURE 2
FIGURE 2
Analysis of non‐small‐cell lung cancer (NSCLC) patients who are ECOG 0–2 and without driver mutation who received immune checkpoint inhibitors (ICIs)
See this image and copyright information in PMC

References

    1. Azizah AM, Hashimah B, Nirmal K, Siti Zubaidah AR, Puteri NA, Nabihah A, et al. Malaysia National Cancer Registry Report (MNCR) 2012‐2016. Putrajaya (Malaysia): Ministry of Health (Malaysia); 2019.
    1. Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non‐small cell lung cancer: a review. JAMA. 2019;322(8):764–74. - PubMed
    1. Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD‐L1‐expressing, locally advanced or metastatic non‐small‐cell lung cancer (KEYNOTE‐042): a randomised, open‐label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–30. - PubMed
    1. Reck M, Rodríguez‐Abreu D, Robinson AG, Hui R, Csoszi T, Fülöp A, et al. Updated analysis of KEYNOTE‐024: pembrolizumab versus platinum‐based chemotherapy for advanced non–small‐cell lung cancer with PD‐L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537–46. - PubMed
    1. Spigel D, De Marinis F, Giaccone G, Reinmuth N, Vergnenegre A, Barrios CH, et al. IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum‐based chemotherapy (chemo) as first‐line (1L) treatment (tx) in PD‐L1–selected NSCLC. Ann Oncol. 2019;30:v915.

Publication types

MeSH terms